Stock analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Trading Up 59,900.0 %
Shares of NAVB opened at $0.06 on Monday. The business’s 50-day moving average is $0.03 and its 200-day moving average is $0.05. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.15.
About Navidea Biopharmaceuticals
Read More
- Five stocks we like better than Navidea Biopharmaceuticals
- Energy and Oil Stocks Explained
- Micron Technology Stock Volatile Despite Analyst Upgrades
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- McDonald’s Stock: Balancing Value and Innovation
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- MarketBeat Week in Review – 6/17 – 6/21
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.